Figures & data
Table I. The influence of 5‐HTTLPR genotype and response to antidepressant drugs. MP = mono/unipolar depression; BP = bipolar disorder.
Table II. Table of genes tested for association with antidepressant response. Y: one positive association reported. YR: positive associations replicated in independent studies. N: so far no positive associations reported.
Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–11 Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5‐HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323–30 Zanardi R., Benedetti F., Di Bella D., Catalano M., Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105–7 Pollock B. G., Ferrell R. E., Mulsant B. H., Mazumdar S., Miller M., Sweet R. A., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late‐life depression. Neuropsychopharmacology 2000; 23: 587–90 Minov C., Baghai T. C., Schule C., Zwanzger P., Schwarz M. J., Zill P., et al. Serotonin‐2A‐receptor and ‐transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119–22 Arias B., Catalan R., Gasto C., Gutierrez B., Fananas L. 5‐HTTLPR polymorphism of the serotonin transporter gene predicts nonremission in major depression patients treated with citalopram in a 12‐weeks follow up study. J Clin Psychopharmacol 2003; 23: 563–7 Joyce P. R., Mulder R. T., Luty S. E., McKenzie J. M., Miller A. L., Rogers G. R., et al. Age‐dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339–46 Durham L. K., Webb S. M., Milos P. M., Clary C. M., Seymour A. B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174: 525–9, Epub 2003 Sep 4 Serretti A., Cusin C., Rossini D., Artioli P., Dotoli D., Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004; 129: 36–40 Kraft J. B., Slager S. L., McGrath P. J., Knowles J. A., Hamilton S. P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374–81 Murphy G. M., Jr., Hollander S. B., Rodrigues H. E., Kremer C., Schatzberg A. F. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163–9 Kim D. K., Lim S. W., Lee S., Sohn S. E., Kim S., Hahn C. G., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–9 Yoshida K., Ito K., Sato K., Takahashi H., Kamata M., Higuchi H., et al. Influence of the serotonin transporter gene‐linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383–6 Yu Y. W., Tsai S. J., Chen T. J., Lin C. H., Hong C. J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115–9 Ito K., Yoshida K., Sato K., Takahashi H., Kamata M., Higuchi H., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002; 111: 235–9 Lee M. S., Lee H. Y., Lee H. J., Ryu S. H. Serotonin transporter promoter gene polymorphism and long‐term outcome of antidepressant treatment. Psychiatr Genet 2004; 14: 111–5 Kato M., Ikenaga Y., Wakeno M., Okugawa G., Nobuhara K., Fukuda T., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005; 20: 151–6